Auditorium. Title: Welcome and Introduction by the Chairs Moderation: M. Pless, A. Cervantes ; Winterthur, CH, Valencia, ES

Size: px
Start display at page:

Download "Auditorium. Title: Welcome and Introduction by the Chairs Moderation: M. Pless, A. Cervantes ; Winterthur, CH, Valencia, ES"

Transcription

1 :45-13:00 Type: Educational session Title: Welcome and Introduction by the Chairs Moderation: M. Pless, A. Cervantes ; Winterthur, CH, Valencia, ES 12:45-13:00 Welcome 13:00-13:15 Type: Educational session Title: Demonstration of the SpotMe interactive tool 13:15-14:20 Type: Educational session Title: Introduction to the ESMO examination 13:15-13:25 How to approach the ESMO Examination 13:25-13:55 Test questions I (with use of interactive Spot me tool) M. Pless 1, C. Waller 2 ; 1 Winterthur, CH, 2 Freiburg, DE 13:55-14:20 Test review and discussion I 14:20-14:45 Type: Educational session Title: Methodology of clinical trials 14:20-14:40 How to read a clinical trial - Interpretation of clinical research data 14:40-14:45 Q&A

2 14:45-15:45 Type: Educational session Title: Standard of care and future perspectives in Prostate cancer 14:45-15:30 Evolving concepts in the management of prostate cancer E. Efstathiou, Houston, Tx, US 15:30-15:45 Q&A 16:15-17:45 Type: Educational session Title: Standard of care and future perspectives in Colorectal cancer Moderation: D. Sebag-Montefiore, London, US 16:15-16:35 Standard of care in pre-op radiation of rectal cancer D. Sebag-Montefiore, London, US 16:35-16:40 Q&A 16:40-17:00 Adjuvant treatment C.-H. Koehne, Oldenburg, DE 17:00-17:05 Q&A 17:05-17:35 Metastatic disease D. Arnold, Lisbon, PT 17:35-17:45 Q&A

3 17:45-18:35 Type: Educational session Title: Standard of care and future perspectives in Sarcoma & GIST Moderation: P. Casali, Milan, IT 17:45-18:05 Sarcoma P. Casali, Milan, IT 18:05-18:10 Q&A 18:10-18:30 GIST J.-Y. Blay, P. Casali ; Lyon, FR, Milan, IT 18:30-18:35 Q&A :30-10:20 Type: Educational session Title: Standard of care and future perspectives in Lung cancer Moderation: B. Besse, Villejuif, FR 08:30-08:50 Stage I-IIIa B. Besse, Villejuif, FR 08:50-09:00 Q&A 09:00-09:45 Metastatic disease S. Peters, Lausanne, CH 09:45-10:00 Q&A 10:00-10:10 SCLC B. Besse, Villejuif, FR 10:10-10:20 Q&A

4 10:50-12:20 Type: Educational session Title: Standard of care and future perspectives in Breast cancer Moderation: S. Aebi, Luzern, CH 10:50-11:25 Neo-adjuvant and adjuvant S. Aebi, Luzern, CH 11:25-11:35 Q&A 11:35-12:10 Metastatic disease G. Curigliano, Milan, IT 12:10-12:20 Q&A 13:20-14:20 Type: Educational session Title: Standard of care and future perspectives in Gynaecological cancer Moderation: J. Ledermann, London, GB 13:20-13:40 Ovarian J. Ledermann, London, GB 13:40-13:50 Q&A 13:50-14:10 Endometrial and cervical N. Colombo, Milano, IT 14:10-14:20 Q&A

5 14:20-15:20 Type: Educational session Title: Standard of care and future perspectives in Renal and Testicular cancer Moderation: C. Porta, Pavia, IT 14:20-14:40 Treatment of clear cell RCC C. Porta, Pavia, IT 14:40-14:50 Q&A 14:50-15:10 Standards in treatment of testicular tumors R. Huddart, Sutton, GB 15:10-15:20 Q&A 15:50-16:35 Type: Educational session Title: Standard of care and future perspectives in Melanoma 15:50-16:25 Melanoma C. Blank, Amsterdam, NL 16:25-16:35 Q&A 16:35-17:05 Type: Educational session Title: Standard of care and future perspectives in Head & Neck cancer 16:35-16:55 Head & Neck cancer M. Merlano, Cuneo, IT 16:55-17:05 Q&A

6 17:05-17:35 Type: Educational session Title: Standard of care and future perspectives in Brain Tumours 17:05-17:25 Current standards in treatment of adult brain tumors M. Weller, Zurich, CH 17:25-17:35 Q&A 17:35-18:20 Type: Educational session Title: Standard of care and future perspectives in Supportive care 17:35-18:15 Supportive care A. Young, Coventry, GB 18:15-18:20 Q&A :30-09:45 Type: Educational session Title: Standard of care and future perspectives in Haematology and Lymphoma 08:30-09:10 Hodgkin's and non-hodgkin's lymphomas A. Stathis, Bellinzona, CH 09:10-09:15 Q&A 09:15-09:40 Multiple myeloma and CLL J. Goede, Zurich, CH 09:40-09:45 Q&A

7 09:45-10:30 Type: Educational session Title: Pharmacokinetics and drug interactions 09:45-10:20 Pharmacotherapy and drug interactions I. Braña, Barcelona, ES 10:20-10:30 Q&A 10:50-12:10 Type: Educational session Title: Standard of care and future perspectives in Upper GI, Pancreatic & non-colorectal cancer 10:50-11:20 Oesophageal and gastric A. Cervantes, Valencia, ES 11:20-11:30 Q&A 11:30-12:00 Pancreas and biliary E. Van Cutsem, Leuven, BE 12:00-12:10 Q&A 12:10-13:10 Type: Educational session Title: Review session 12:10-12:40 Test questions II C. Waller, Freiburg, DE 12:40-13:10 Test review and discussion II 13:10-13:20 Type: Educational session Title: Closing remarks Moderation: M. Pless, A. Cervantes ; Winterthur, CH, Valencia, ES

S. Rauh 1, J. Douillard 2 ; 1 Esch Sur Alzette, LU, 2 Lugano - Viganello, CEDEX/CH

S. Rauh 1, J. Douillard 2 ; 1 Esch Sur Alzette, LU, 2 Lugano - Viganello, CEDEX/CH 27.04.2018 10:30-10:45 Opening and welcome Sala B Moderation: S. Rauh, J. Douillard ; Esch Sur Alzette, LU, Lugano - Viganello, CEDEX/CH 10:30-10:45 Welcome to the Symposium S. Rauh 1, J. Douillard 2 ;

More information

Moderation: S. Rauh, D. Arnold ; Esch, LU, Lisbon, PT. Moderation: S. Rauh, Esch, LU

Moderation: S. Rauh, D. Arnold ; Esch, LU, Lisbon, PT. Moderation: S. Rauh, Esch, LU 03-03-2017 13:30-13:45 Opening and welcome Auditorium Moderation: S. Rauh, D. Arnold ; Esch, LU, Lisbon, PT 13:30-13:45 Welcome to the Conference 13:45-14:15 Keynote lecture Auditorium Moderation: 13:45-14:15

More information

S. Rauh 1, J. Douillard 2 ; 1 Esch Sur Alzette, LU, 2 Lugano - Viganello, CEDEX/CH

S. Rauh 1, J. Douillard 2 ; 1 Esch Sur Alzette, LU, 2 Lugano - Viganello, CEDEX/CH 27.04.2018 10:30-10:45 Opening and welcome Sala B Moderation: S. Rauh, J. Douillard ; Esch Sur Alzette, LU, Lugano - Viganello, CEDEX/CH 10:30-10:45 Welcome and introduction S. Rauh 1, J. Douillard 2 ;

More information

CLINICAL ONCOLOGY March 2012 Ermatingen (Lake Constance), Switzerland

CLINICAL ONCOLOGY March 2012 Ermatingen (Lake Constance), Switzerland MASTERCLASS ERMATINGEN 17/03/12 11 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY 17-22 March 2012 Ermatingen (Lake Constance), Switzerland Chairs: N. Pavlidis, GR - R.A. Stahel, CH Scientific Co-ordinators:

More information

ONCOLOGY NURSING 9 TH ESO-EONS MASTERCLASS IN March 2016 Ermatingen (Lake Constance) Switzerland #16MON

ONCOLOGY NURSING 9 TH ESO-EONS MASTERCLASS IN March 2016 Ermatingen (Lake Constance) Switzerland #16MON MASTERCLASS Photo: Turm by Stephan Balkenhol - A Sculpture for Wolfsberg Photographer: Ralph Feiner, Architekturfotografie, Malans 9 TH ESO-EONS MASTERCLASS IN ONCOLOGY NURSING 12-17 March 2016 Ermatingen

More information

ESMO-ESO Course on Medical Oncology for Medical Students Educational Programme July 2016, Valencia, Spain

ESMO-ESO Course on Medical Oncology for Medical Students Educational Programme July 2016, Valencia, Spain ESMO-ESO Course on Medical Oncology for Medical Students Educational Programme 14-19 July 2016, Valencia, Spain Co-chairs: Andrés Cervantes, ES - Nicholas Pavlidis, GR - Susana Banerjee, UK Thursday, 14

More information

4 TH ESO-ESMO LATIN-AMERICAN MASTERCLASS IN CLINICAL ONCOLOGY April 2018 Mexico City, Mexico LATIN-AMERICA PROGRAMME

4 TH ESO-ESMO LATIN-AMERICAN MASTERCLASS IN CLINICAL ONCOLOGY April 2018 Mexico City, Mexico LATIN-AMERICA PROGRAMME 4 TH ESO-ESMO LATIN-AMERICAN MASTERCLASS IN CLINICAL ONCOLOGY 18-22 April 2018 Mexico City, Mexico Chairs: A. Cervantes, ES - N. Pavlidis, GR R.A. Stahel, CH Scientific Co-ordinators: M. Aapro, CH - F.

More information

10 th ESO-EONS MASTERCLASS IN ONCOLOGY NURSING march 2017 nauen ot Groß Behnitz (Berlin area), Germany. masterclass

10 th ESO-EONS MASTERCLASS IN ONCOLOGY NURSING march 2017 nauen ot Groß Behnitz (Berlin area), Germany. masterclass 10 th ESO-EONS MASTERCLASS IN ONCOLOGY NURSING 25-30 march 2017 nauen ot Groß Behnitz (Berlin area), Germany Chairs: B. Grube, DK - C. Lacerda, PT Coordinator: E. van Muilekom, NL Advisor: masterclass

More information

NOSCAN CLINICAL MANAGEMENT GUIDELINE (CMG) AND NOSCAN CHEMOTHERAPY REVIEW (NCR) STATUS DOCUMENT May Status (G / A / R) Status (G / A / R)

NOSCAN CLINICAL MANAGEMENT GUIDELINE (CMG) AND NOSCAN CHEMOTHERAPY REVIEW (NCR) STATUS DOCUMENT May Status (G / A / R) Status (G / A / R) Item 18-13c NOSCAN CLINICAL MANAGEMENT GUIDELINE (CMG) AND NOSCAN CHEMOTHERAPY REVIEW (NCR) STATUS DOCUMENT May 2013 BREAST CANCER MCN: Breast Disease: Breast Document ready to circulate lead to be discussed

More information

3RD ESO-ESMO LATIN-AMERICAN MASTERCLASS IN CLINICAL ONCOLOGY April 2017 San Jose, Costa Rica LATIN-AMERICA PROGRAMME

3RD ESO-ESMO LATIN-AMERICAN MASTERCLASS IN CLINICAL ONCOLOGY April 2017 San Jose, Costa Rica LATIN-AMERICA PROGRAMME 3RD ESO-ESMO LATIN-AMERICAN MASTERCLASS IN CLINICAL ONCOLOGY 26-30 April 2017 San Jose, Costa Rica Chairs: A. Cervantes, ES - N. Pavlidis, GR R.A. Stahel, CH Scientific Co-ordinators: M. Aapro, CH - F.

More information

ESO-ASCO MASTERCLASS IN CLINICAL ONCOLOGY November 2018 Yerevan, Armenia MASTERCLASS

ESO-ASCO MASTERCLASS IN CLINICAL ONCOLOGY November 2018 Yerevan, Armenia MASTERCLASS ESO-ASCO MASTERCLASS IN CLINICAL ONCOLOGY 10-13 November 2018 Yerevan, Armenia Chairs: G. Curigliano, IT F. Peccatori, IT Host Chair: G. Tamamyan, AM Held in collaboration with MASTERCLASS AIMS AND OBJECTIVES

More information

ROOM: CONRAD + ARNOLD. ROOM: CONRAD + ARNOLD Focus on ESO, ESMO and EONS Nicholas Pavlidis, Rolf Stahel,

ROOM: CONRAD + ARNOLD. ROOM: CONRAD + ARNOLD Focus on ESO, ESMO and EONS Nicholas Pavlidis, Rolf Stahel, 17h ESO-ESMO Masterclass in Clinical Oncology 24-29 March 2018, Berlin, Germany In collaboration with the Flims Alumni Club Chair: Nicholas Pavlidis, GR and Rolf A. Stahel, CH Scientific Advisors: R. Popescu,

More information

Gastric Cancer Co-Chairs Speakers LEARNING OBJECTIVES

Gastric Cancer Co-Chairs Speakers LEARNING OBJECTIVES ESMO Preceptorship Programme Gastric Cancer Multidisciplinary management, standards of care, therapeutic targets and future perspectives 10-11 June 2016, Prague, Czech Republic Co-Chairs Andres Cervantes

More information

3RD ESO-ESMO LATIN-AMERICAN MASTERCLASS IN CLINICAL ONCOLOGY April 2017 San Jose, Costa Rica LATIN-AMERICA PROGRAMME

3RD ESO-ESMO LATIN-AMERICAN MASTERCLASS IN CLINICAL ONCOLOGY April 2017 San Jose, Costa Rica LATIN-AMERICA PROGRAMME 3RD ESO-ESMO LATIN-AMERICAN MASTERCLASS IN CLINICAL ONCOLOGY 26-30 April 2017 San Jose, Costa Rica Chairs: A. Cervantes, ES - N. Pavlidis, GR R.A. Stahel, CH Scientific Co-ordinators: M. Aapro, CH - F.

More information

Berlin. Title: Industry Satellite Symposium. Vienna. Title: Industry Satellite Symposium. Exhibition area. Title: Welcome reception

Berlin. Title: Industry Satellite Symposium. Vienna. Title: Industry Satellite Symposium. Exhibition area. Title: Welcome reception 02.05.2019 12:00-13:00 Type: Industry Satellite Symposium 12:00-13:00 Type: Industry Satellite Symposium 13:00-13:30 Type: Opening session Title: Welcome reception Exhibition area 13:30-13:45 Type: Opening

More information

ONCOLOGY NURSING 6 TH ESO-EONS MASTERCLASS IN March 2013 Ermatingen (Lake Constance) Switzerland MASTERCLASS

ONCOLOGY NURSING 6 TH ESO-EONS MASTERCLASS IN March 2013 Ermatingen (Lake Constance) Switzerland MASTERCLASS MASTERCLASS Photo: Turm by Stephan Balkenhol - A Sculpture for Wolfsberg Photographer: Ralph Feiner, Architekturfotografie, Malans 6 TH ESO-EONS MASTERCLASS IN ONCOLOGY NURSING 16-21 March 2013 Ermatingen

More information

CO-CHAIRS: Andrés Cervantes, Spain Jean-Yves Douillard, France

CO-CHAIRS: Andrés Cervantes, Spain Jean-Yves Douillard, France ESMO Preceptorship Programme Colorectal Cancer Multidisciplinary management, standards of care and future perspectives Prague, Czech Republic 6-7 July 2016 CO-CHAIRS: Andrés Cervantes, Spain Jean-Yves

More information

Are the ESMO guidelines adapted to the elderly? D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium

Are the ESMO guidelines adapted to the elderly? D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium Are the ESMO guidelines adapted to the elderly? D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium Clinical practice guidelines Definition > Systemically developed statements

More information

Hall 406. Title: Opening & Keynote. Hall 405. Title: Treatment of node positive bladder. Hall 404

Hall 406. Title: Opening & Keynote. Hall 405. Title: Treatment of node positive bladder. Hall 404 23-11-2018 10:00-11:30 Type: Opening session Title: Opening & Keynote Hall 406 11:45-12:30 Type: Challenge Your Expert session Title: Treatment of node positive bladder 11:45-11:55 Treatment of node positive

More information

Macmillan Publications

Macmillan Publications S1 S2 S3 S3 S3 S4 S5 S6 S7 S8 S8 S9 S10 S11 S11 S12 S13 S14 S15 S17 S18 S19 Bladder Cancer: Non-Invasive, Invasive and Advanced Bone Cancer: Primary, Secondary Colon Cancer, Anal Cancer, Rectal Cancer

More information

Fortunato Ciardiello. ESMO and Congress President

Fortunato Ciardiello. ESMO and Congress President OPENING SESSION Fortunato Ciardiello ESMO and Congress President 2 3 ONE DREAM 23,000 participants 4 ESMO: 42 YEARS OF EXCELLENCE 2005-2017 5 ESMO: a membercentric society 6 7 ESMO STAFF Anton Berns

More information

ESMO Symposium on Immuno-Oncology Programme book

ESMO Symposium on Immuno-Oncology Programme book IMMUNO-ONCOLOGY SYMPOSIUM ESMO Symposium on Immuno-Oncology Programme book Advances in cancer immunotherapy; From vaccines to antibodies and cell therapies Geneva Switzerland 15-16 NOVEMBER 2013 esmo.org

More information

High risk non-muscle invasive bladder cancer: From guidelines to future approaches Chairs: A. Lopez Beltran, Lisbon (PT)

High risk non-muscle invasive bladder cancer: From guidelines to future approaches Chairs: A. Lopez Beltran, Lisbon (PT) Friday, 8 June 2018 EAU Update on Bladder Cancer (BCa18) Challenging your knowledge of the EAU Guidelines 8-9 June 2018, Munich, Germany Steering committee: F. Montorsi, H. Van Poppel and M. Wirth Scientific

More information

ESMO Clinical Practice Guidelines. ECCO GUIDELINES FORUM Brussels, November 27

ESMO Clinical Practice Guidelines. ECCO GUIDELINES FORUM Brussels, November 27 ESMO Clinical Practice Guidelines ECCO GUIDELINES FORUM Brussels, November 27 ESMO Clinical Practice Guidelines ESMO Consensus Conferences ESMO Pocket & Mobile Guidelines ESMO Guides for Patients History

More information

FACULTY MEMBERSHIP APPLICATION Tulane Cancer Center

FACULTY MEMBERSHIP APPLICATION Tulane Cancer Center FACULTY MEMBERSHIP APPLICATION Tulane Cancer Center 1430 Tulane Ave., Box SL-68, New Orleans, LA 70112-2699 J. Bennett Johnston Building, Mezzanine (Floor 1A), Suite A102 (504) 988-6060, fax (504) 988-6077,

More information

National Cancer Drugs Fund List - Approved

National Cancer Drugs Fund List - Approved National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer

More information

2008 Oncology Pharmacy Preparatory Review Course Learning Objectives

2008 Oncology Pharmacy Preparatory Review Course Learning Objectives 2008 Oncology Pharmacy Preparatory Review Course Learning Objectives Session 1 Symptom Management, Part I, II & III Teresa A. Mays, Pharm D., BCOP Director, Investigational Drug Department San Antonio,

More information

Outcomes Report: Accountability Measures and Quality Improvements

Outcomes Report: Accountability Measures and Quality Improvements Outcomes Report: Accountability Measures and Quality Improvements The FH Memorial Medical Center s Cancer Committee ensures that patients with cancer are treated according to the nationally accepted measures.

More information

oncology For 9 th eso-esmo course on July 2012 ioannina, Greece

oncology For 9 th eso-esmo course on July 2012 ioannina, Greece ESO ADVANCED COURSES, SEMINARS AND SYMPOSIA ioannina 21/07/12 9 th eso-esmo course on oncology For medical students 21-27 July 2012 ioannina, Greece chair: N. Pavlidis, GR core faculty: R.A. Audisio, UK

More information

ESOU programme Prostate cancer screening: Why screening programme should not be adopted in > 65 A. Heidenreich, Aachen (DE)

ESOU programme Prostate cancer screening: Why screening programme should not be adopted in > 65 A. Heidenreich, Aachen (DE) Friday, 17 January 08.30-08.40 Welcome M. Babjuk, Prague (CZ) M. Brausi, Modena (IT) 08.40-09.00 Opening address ESOU programme 09.00-11.00 Prostate cancer I: Screening, diagnosis, staging and treatment

More information

Review on Tumour Doubling Time (DT) To review the studies that measuring the actual tumour doubling time for human cancers.

Review on Tumour Doubling Time (DT) To review the studies that measuring the actual tumour doubling time for human cancers. Review on Tumour Doubling Time (DT) Objective To review the studies that measuring the actual tumour doubling time for human cancers. Methods We searched the Medline database from January 1966 to January

More information

ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe Preliminary Findings

ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe Preliminary Findings ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe Preliminary Findings Nathan I Cherny Norman Levan Chair in Humanistic Medicine Dept Oncology

More information

CANCER INCIDENCE AND SURVIVAL STATISTICS FOR NORTHERN IRELAND

CANCER INCIDENCE AND SURVIVAL STATISTICS FOR NORTHERN IRELAND 12 March 2019 CANCER INCIDENCE AND SURVIVAL STATISTICS FOR NORTHERN IRELAND 1993-2017 Official Statistics on cancers diagnosed in Northern Ireland during 1993-2017 were published today. This release provides

More information

Exploring the healthcare cost implications of cancer stage. England level modelling

Exploring the healthcare cost implications of cancer stage. England level modelling Exploring the healthcare cost implications of cancer stage England level modelling Rachel White (Rwhite@macmillan.org.uk) Thursday 22 nd September 2016 What we re covering Modelling methods Results - variation

More information

Day 1: ESMO Sarcoma & GIST Faculty closed meeting

Day 1: ESMO Sarcoma & GIST Faculty closed meeting Day 1: ESMO Sarcoma & GIST Faculty closed meeting Sunday, 4 February 2018 12:30 14:00 Lunch 14:00-16:00 Discussion: Should we routinely use NGS? 120 Panel discussion 16:00 16:30 Coffee Break 16:30-18:00

More information

Amphithéâtre Bordeaux. Amphithéâtre. C. Massard, Villejuif, CEDEX/FR. N. Rizvi, New York, NY/US

Amphithéâtre Bordeaux. Amphithéâtre. C. Massard, Villejuif, CEDEX/FR. N. Rizvi, New York, NY/US 25.02.2019 08:45-09:30 Opening and welcome + Honorary award Keynote lecture 08:45-08:55 Welcome address 08:55-09:00 Presentation of the TAT 2019 Honorary Award 09:00-09:30 TAT 2018 Honorary Award Keynote

More information

MEDICAL ONCOLOGY ESO-ESMO EASTERN EUROPE AND BALKAN REGION MASTERCLASS IN. 27 June - 2 July 2014 Brdo, Slovenia. Chairs: T. Cufer, SI R.

MEDICAL ONCOLOGY ESO-ESMO EASTERN EUROPE AND BALKAN REGION MASTERCLASS IN. 27 June - 2 July 2014 Brdo, Slovenia. Chairs: T. Cufer, SI R. Flyer MMO_(4 Mar)_screen 04.04.2014 09:33 Pagina 3 MASTERCLASS ESO-ESMO EASTERN EUROPE AND BALKAN REGION MASTERCLASS IN MEDICAL ONCOLOGY 27 June - 2 July 2014 Brdo, Slovenia Chairs: R. Herrmann, CH This

More information

Cancer prevalence. Chapter 7

Cancer prevalence. Chapter 7 Chapter 7 Cancer prevalence Prevalence measures the number of people diagnosed with cancer who are still alive. This chapter presents current and historical statistics on cancer prevalence in Ontario.

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Chacón MR, Enrico DH, Burton J, Waisberg FD, Videla VM. Incidence of placebo adverse events in randomized clinical trials of targeted and immunotherapy cancer drugs in the

More information

Phase-specific Costs of Cancer Care in Ontario

Phase-specific Costs of Cancer Care in Ontario Phase-specific Costs of Cancer Care in Ontario Canadian Association of Health Services and Policy Research Conference Session: D5 Cancer Care Wednesday May 29 2013 Claire de Oliveira, M.A. PhD Background

More information

CASE DISCUSSION ON GASTRIC CANCER BASED ON ESMO GUIDELINES

CASE DISCUSSION ON GASTRIC CANCER BASED ON ESMO GUIDELINES ESMO Preceptorship GI Tumours Singapore 20-22 nd October CASE DISCUSSION ON GASTRIC CANCER BASED ON ESMO GUIDELINES Professor. J-Y. Douillard MD PhD ESMO Chief Medical Officer CLINICAL PRACTICE GUIDELINES

More information

National Cancer Patient Experience Survey 2016 Technical Documentation July 2017

National Cancer Patient Experience Survey 2016 Technical Documentation July 2017 National Cancer Patient Experience Survey 2016 Technical Documentation July 2017 1 Contents 1. Introduction 2. Scoring 3. Significance Tests (for national data) 4. Case-mix Adjustment (for local data)

More information

Room A. Title: Introduction to immunotherapy in cancer Chair(s): K. Kerr, GB; P. Romero, CH. Room A. Title: Opening and welcome.

Room A. Title: Introduction to immunotherapy in cancer Chair(s): K. Kerr, GB; P. Romero, CH. Room A. Title: Opening and welcome. 13.12.2018 11:15-12:45 Type: Educational session Title: Introduction to immunotherapy in cancer Chair(s): K. Kerr, GB; P. Romero, CH 11:15-11:35 Back to the basics P. Romero, Epalinges, CH 11:35-11:55

More information

Contents. 3 Pneumology Introduction Positron Emission Tomography: Past and Present 1. 2 Fundamentals. xxx

Contents. 3 Pneumology Introduction Positron Emission Tomography: Past and Present 1. 2 Fundamentals. xxx xxx IX Contents 1 Introduction Positron Emission Tomography: Past and Present 1 1.1 Survey.......................... 1 Physical and Biochemical Fundamentals.... 2 PET in National and International Medical

More information

Life & Bladder Cancer - The Yorkshire Survey

Life & Bladder Cancer - The Yorkshire Survey Life & BC Life & Bladder Cancer - The Yorkshire Survey Prof. James Catto University of Sheffield Prostate Colon Bladder Lung Renal NHL Oral cavity Melanoma Leukaemia Bladder Cancer - Prevalence 400000

More information

DEPARTMENT OF ONCOLOGY ELECTIVE

DEPARTMENT OF ONCOLOGY ELECTIVE DEPARTMENT OF ONCOLOGY ELECTIVE 2015-2016 www.uwo.ca/oncology Oncology Elective Program Administrator: Ms. Kimberly Trudgeon Room A4-901C (Admin) LHSC London Regional Cancer Centre (Victoria Campus) Phone:

More information

List of Available TMAs in the PRN

List of Available TMAs in the PRN TMA RPCI_BrainCa01 RPCI_BrCa03 RPCI_BrCa04 RPCI_BrCa05 RPCI_BrCa0 RPCI_BrCa07 RPCI_BrCa08 RPCI_BrCa15 RPCI_BrCa1 RPCI_BrCa17 RPCI_BrCa18 RPCI_BrCa19 RPCI_BrCa20 RPCI_BrCa21 RPCI_BrCa24 RPCI_BrCa25 RPCI_BrCa2

More information

National Cancer Registration and Analysis Service Short Report: Chemotherapy, Radiotherapy and Surgical Tumour Resections in England: (V2)

National Cancer Registration and Analysis Service Short Report: Chemotherapy, Radiotherapy and Surgical Tumour Resections in England: (V2) National Cancer Registration and Analysis Service Short Report: Chemotherapy, Radiotherapy and Surgical Tumour Resections in England: 13-14 (V2) Produced as part of the Cancer Research UK - Public Health

More information

HEALTHCARE CLAIMS TRACKER A FOCUS ON ONCOLOGY CLAIMS. September 2018 For the period January 2017 December 2017

HEALTHCARE CLAIMS TRACKER A FOCUS ON ONCOLOGY CLAIMS. September 2018 For the period January 2017 December 2017 HEALTHCARE A FOCUS ON CLAIMS September 208 For the period January 207 December 207 INTRODUCTION Cancer is one of the leading causes of death both globally and in South Africa. Worldwide, one in seven deaths

More information

Identifying and counting people living with treatable but not curable cancer

Identifying and counting people living with treatable but not curable cancer Identifying and counting people living with treatable but not curable cancer Rachel White Joanna Pethick, Archie Macnair, Gregory Fallica, Jennifer Than and Jane Maher September 2018 Who are the people

More information

Development status of OPDIVO (nivolumab) 1

Development status of OPDIVO (nivolumab) 1 August 1, 2018 Development status of OPDIVO (nivolumab) 1 Target disease JAPAN US/EU KR/TW Melanoma (1 st ) Approved Approved Approved Melanoma (Adjuvant Therapy) Filing Approved (US) Non-small cell lung

More information

Information Services Division NHS National Services Scotland

Information Services Division NHS National Services Scotland Cancer in Scotland April 2017 First published in June 2004, revised with each National Statistics publication Next due for revision October 2017 Information Services Division NHS National Services Scotland

More information

H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS

H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS Each of you should have 37 new cards: 7 orange cards for antimetabolites 11 white cards for miscellaneous drugs (2 DNA synthesis inhibitors, 1 enzyme,

More information

ONCOLOGY NURSING March 2012 Ermatingen (Lake Constance), Switzerland

ONCOLOGY NURSING March 2012 Ermatingen (Lake Constance), Switzerland MASTERCLASS ERMATINGEN 17/03/12 5 TH ESO-EONS MASTERCLASS IN ONCOLOGY NURSING 17-22 March 2012 Ermatingen (Lake Constance), Switzerland Chairs: A. Margulies, CH - S. Faithfull, UK Scientific Coordinator:

More information

Short Study Report for Health Authorities

Short Study Report for Health Authorities the Active Title of the Study Randomised trial of single agent doxorubicin versus doxorubicin plus ifosfamide in the first line treatment of advanced or metastatic soft tissue sarcoma Investigators & Study

More information

Outcomes Report: Accountability Measures and Quality Improvements

Outcomes Report: Accountability Measures and Quality Improvements Outcomes Report: Accountability Measures and Quality Improvements The s Cancer Committee ensures that patients with cancer are treated according to the nationally accepted measures. Because we are an accredited

More information

Monday, 5 February 2018

Monday, 5 February 2018 Educational sessions for Junior audience Monday, 5 February 2018 09:30-11:00 Session 1 The diseases Chairs: Paolo. G Casali, IT; Paula Collini, IT 25 The natural history of STS & GIST Paolo. G Casali,

More information

The table below presents the summary of observed geographic variation for incidence and survival by type of cancer and gender.

The table below presents the summary of observed geographic variation for incidence and survival by type of cancer and gender. Results and Maps Overview When disparities in cancer incidence and survival are evident, there are a number of potential explanations, including but not restricted to differences in environmental risk

More information

ALL CANCER (EXCLUDING NMSC)

ALL CANCER (EXCLUDING NMSC) ALL CANCER (EXCLUDING NMSC) AVERAGE NUMBER OF CASES PER YEAR (2011-2015) AVERAGE NUMBER OF DEATHS PER YEAR (2011-2015) Male Female Both sexes Male Female Both sexes 4,557 4,516 9,073 1 2,196 1,984 4,180

More information

Cancer Prevention & Control in Adolescent & Young Adult Survivors

Cancer Prevention & Control in Adolescent & Young Adult Survivors + Cancer Prevention & Control in Adolescent & Young Adult Survivors NCPF Workshop July 15-16, 2013 Patricia A. Ganz, MD UCLA Schools of Medicine & Public Health Jonsson Comprehensive Cancer Center + Overview

More information

PRECEPTORSHIP PROGRAMME

PRECEPTORSHIP PROGRAMME esmo.org PRECEPTORSHIP PROGRAMME Gastrointestinal Tumours Multidisciplinary management, standards of care and future perspectives SINGAPORE 20-22 OCTOBER 2016 Co-Chairs Jean-Yves Douillard, Switzerland

More information

Trends in Cancer Survival in NSW 1980 to 1996

Trends in Cancer Survival in NSW 1980 to 1996 Trends in Cancer Survival in NSW 19 to 1996 Xue Q Yu Dianne O Connell Bruce Armstrong Robert Gibberd Cancer Epidemiology Research Unit Cancer Research and Registers Division The Cancer Council NSW August

More information

Information Services Division NHS National Services Scotland

Information Services Division NHS National Services Scotland Cancer in Scotland April 2013 First published in June 2004, revised with each National Statistics publication Next due for revision October 2013 Information Services Division NHS National Services Scotland

More information

Development status of OPDIVO (nivolumab) 1

Development status of OPDIVO (nivolumab) 1 November 2, 2018 Development status of OPDIVO (nivolumab) 1 Target disease JAPAN US/EU KR/TW Melanoma (1 st ) Approved Approved Approved Melanoma (Adjuvant Therapy) Approved Approved(EU) Non-small cell

More information

Index. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.

Index. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type. Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic

More information

Pancreat ic Cancer UK. policy briefing. A cancer of unmet need: the pancreatic cancer research challenge

Pancreat ic Cancer UK. policy briefing. A cancer of unmet need: the pancreatic cancer research challenge Pancreat ic Cancer UK policy briefing A cancer of unmet need: the pancreatic cancer research challenge Introduction Pancreatic Cancer UK s Study for Survival, launched in 2011, marked the first ever comprehensive

More information

2010 Oncology Pharmacy Preparatory Review Course for Home Study Learning Objectives

2010 Oncology Pharmacy Preparatory Review Course for Home Study Learning Objectives 2010 Oncology Pharmacy Preparatory Review Course for Home Study Learning Objectives Acute Leukemia/Tumor Lysis Syndrome John M. Valgus, Pharm.D., BCOP Hematology/Oncology Specialist University of North

More information

Top Regimens by Diagnostic Group. April July 2012

Top Regimens by Diagnostic Group. April July 2012 Top Regimens by Diagnostic Group April July 2012 Introduction The Top Regimens by Diagnostic Group report provides an overview of the most frequently administered regimens for major tumour sites. Within

More information

ALL CANCER (EXCLUDING NMSC)

ALL CANCER (EXCLUDING NMSC) ALL CANCER (EXCLUDING NMSC) AVERAGE NUMBER OF CASES PER YEAR (2012-2016) AVERAGE NUMBER OF DEATHS PER YEAR (2012-2016) Male Female Both sexes Male Female Both sexes 4,607 4,632 9,240 1 2,238 2,036 4,274

More information

Overview of 2009 Hong Kong Cancer Statistics

Overview of 2009 Hong Kong Cancer Statistics Overview of 2009 Hong Kong Cancer Statistics Cancer Registration in Hong Kong The Hong Kong Cancer Registry has since 1963 been providing population-based cancer data for epidemiological research and healthcare

More information

Re-audit of Radiotherapy Waiting Times 2005

Re-audit of Radiotherapy Waiting Times 2005 Abstract Re-audit of Radiotherapy Waiting Times 2005 E. Summers, M Williams Royal College of Radiologists, 38 Portland Place, London W1B 4JQ, UK Aim: To determine current waiting times for radiotherapy

More information

Trends in cancer incidence in South East England Henrik Møller and all staff at the Thames Cancer Registry, King s College London

Trends in cancer incidence in South East England Henrik Møller and all staff at the Thames Cancer Registry, King s College London Trends in cancer incidence in South East England 1960-2009 Henrik Møller and all staff at the Thames Cancer Registry, King s College London 1 2 3 Analysts Vicki Coupland Ruth Jack Margreet Lüchtenborg

More information

Information Services Division NHS National Services Scotland

Information Services Division NHS National Services Scotland Cancer in Scotland October 2012 First published in June 2004, revised with each National Statistics publication Next due for revision April 2013 Information Services Division NHS National Services Scotland

More information

Merck Oncology Overview ASCO 2017

Merck Oncology Overview ASCO 2017 Merck Oncology Overview ASCO 217 June 5, 217 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, NJ, USA (the company ) includes forward-looking

More information

Merck Oncology Overview ASCO 2017

Merck Oncology Overview ASCO 2017 Merck Oncology Overview ASCO 217 June 5, 217 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, NJ, USA (the company ) includes forward-looking

More information

The Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb

The Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb Immune Checkpoint Inhibitors Conference, March

More information

W. Eberhardt, Essen, DE. M. Pless, Winterthur, CH. D. De Ruysscher, Maastricht, NL. Moderation: R. Rami-Porta, Terrassa, Barcelona/ES

W. Eberhardt, Essen, DE. M. Pless, Winterthur, CH. D. De Ruysscher, Maastricht, NL. Moderation: R. Rami-Porta, Terrassa, Barcelona/ES 10.04.2019 12:00-13:00 Industry Satellite Symposium 1 Room A 13:00-13:30 Welcome reception Hall 1 13:30-13:45 Opening and welcome Room B 13:45-14:15 HHH Award lecture Room B 13:45-14:15 HHH Award lecture

More information

Overview of 2010 Hong Kong Cancer Statistics

Overview of 2010 Hong Kong Cancer Statistics Overview of 2010 Hong Kong Cancer Statistics Cancer Registration in Hong Kong The Hong Kong Cancer Registry has since the 1960s been providing population-based cancer data for epidemiological research

More information

World Health Organization: Essential Medicines and Devices for Cancer:

World Health Organization: Essential Medicines and Devices for Cancer: World Health Organization: Essential Medicines and Devices for Cancer: Principles, Methodologies, and Outcomes Lawrence N. Shulman, MD Abramson Cancer Center, University of Pennsylvania Partners In Health

More information

Oncology 101. Cancer Basics

Oncology 101. Cancer Basics Oncology 101 Cancer Basics What Will You Learn? What is Cancer and How Does It Develop? Cancer Diagnosis and Staging Cancer Treatment What is Cancer? Cancer is a group of more than 100 different diseases

More information

PRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019

PRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019 MONDAY, JUNE 3, 2019 7:30 AM - 9:15 AM HIGHLIGHTS OF THE DAY 8:00 AM - 9:00 AM S 8:00 AM - 9:15 AM S S 8:00 AM - 11:00 AM S Highlights of the Day Session II Bringing New and Innovative Glioblastoma Treatments

More information

List of Qualifying Conditions

List of Qualifying Conditions List of Qualifying Conditions Cancer Conditions 1) Adrenal cancer 2) Bladder cancer 3) Bone cancer all forms 4) Brain cancer 5) Breast cancer 6) Cervical cancer 7) Colon cancer 8) Colorectal cancer 9)

More information

STEPHEN P. NONN OFFICE OF THE CORONER MADISON COUNTY, ILLINOIS 157 MAIN STREET SUITE 354 EDWARDSVILLE, IL

STEPHEN P. NONN OFFICE OF THE CORONER MADISON COUNTY, ILLINOIS 157 MAIN STREET SUITE 354 EDWARDSVILLE, IL MAIN OFFICE: (618) 692-7478 MORGUE: (618) 296-4525 FAX: (618) 692-6042 FAX: (618) 692-9304 STEPHEN P. NONN OFFICE OF THE CORONER MADISON COUNTY, ILLINOIS 157 MAIN STREET SUITE 354 EDWARDSVILLE, IL. 62025-1962

More information

An introduction to the Essential Medicines concept: balancing innovation with public health priorities

An introduction to the Essential Medicines concept: balancing innovation with public health priorities An introduction to the Essential Medicines concept: balancing innovation with public health priorities World Oncology Forum Lugano 20 October 2017 Nicola Magrini Secretary, WHO Expert Committee on the

More information

Cancer in Ireland with estimates for

Cancer in Ireland with estimates for Cancer in Ireland 1994-2015 with estimates for 2015-2017: Annual Report of the National Cancer Registry 2017 Page ABBREVIATIONS 95% CI 95% confidence interval APC Annual percentage change ASR Age-standardised

More information

Phase-specific Net Costs of Cancer Care in Ontario. Claire de Oliveira, M.A. PhD

Phase-specific Net Costs of Cancer Care in Ontario. Claire de Oliveira, M.A. PhD Phase-specific Net Costs of Cancer Care in Ontario Claire de Oliveira, M.A. PhD Background Cancer: leading cause of death in Canada with costly implications for government and patients Cost estimates of

More information

Cancer Endorsement Maintenance 2011-Maintenance Measures

Cancer Endorsement Maintenance 2011-Maintenance Measures Measure Number Title Description Measure Steward 0210 Proportion receiving chemotherapy in the last 14 days of life 0211 Proportion with more than one emergency room visit in the last days of life 0212

More information

Colorectal Cancer Multidisciplinary management, standards of care and future perspectives

Colorectal Cancer Multidisciplinary management, standards of care and future perspectives ESMO Preceptorship Programme Colorectal Cancer Multidisciplinary management, standards of care and future perspectives Prague, Czech Republic 6-7 July 2016 CO-CHAIRS: Andrés Cervantes, Spain Jean-Yves

More information

Tumor Markers Yesterday, Today & Tomorrow. Steven E. Zimmerman M.D. Vice President & Chief Medical Director

Tumor Markers Yesterday, Today & Tomorrow. Steven E. Zimmerman M.D. Vice President & Chief Medical Director Tumor Markers Yesterday, Today & Tomorrow Steven E. Zimmerman M.D. Vice President & Chief Medical Director Tumor Marker - Definition Substances produced by cancer cells or other cells in response to cancer

More information

Cancer in Huron County

Cancer in Huron County Cancer in Huron County 2-29 Prepared by: Erica Clark, Epidemiologist April 214 77722B London Road RR 5, Clinton, ON NM 1L 519.482.3416 F: 519.482.782 www.huronhealthunit.com Cancer Health Status Report

More information

Zurich, January 19, 2018

Zurich, January 19, 2018 Brain metastases as first presentation of malignancy: Immediate management, differential diagnosis; prevalence of primaries and suggested work-up Symposium on Brain Metastasis Cancer Center Zurich Zurich,

More information

Development Pipeline Progress Status. February 1, 2019

Development Pipeline Progress Status. February 1, 2019 Development Pipeline Progress Status February 1, 2019 /9 Development status of OPDIVO (nivolumab) (1) Target disease JAPAN US/EU KR/TW Melanoma (1 st ) Approved Approved Approved Melanoma (Adjuvant Therapy)

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Supplementary nformation S3 Combinations including two or more immunotherapy agents based on PD-1/PD-L1 blockade. (Source: https://clinicaltrials.gov/

More information

Merck Oncology Overview. The Development of MSI-H Cancer Therapy. Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 2017

Merck Oncology Overview. The Development of MSI-H Cancer Therapy. Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 2017 Merck Oncology Overview The Development of MSI-H Cancer Therapy Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 217 Andrew Joe, MD Executive Director, Late Stage Oncology Merck & Co.,

More information

Supplemental Table 1.1: Prostate cancer prognostic tools

Supplemental Table 1.1: Prostate cancer prognostic tools Supplemental Table 1.1: Prostate cancer prognostic tools Features ANN^ BioChemical Capra^ CSQS EBRT Han Outcomes Cancer Specific - - +* + - - Non-Cancer Specific - - - + - - DFS/PFS +* +* +* - +* +* Clinical

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Henson KE, Brock R, Charnock J, Wickramasinghe B, Will O, Pitman A. Risk of suicide after cancer diagnosis in England. JAMA Psychiatry. Published online November 21, 2018.

More information

Figure 1: Consort diagram; the status of participants in the study

Figure 1: Consort diagram; the status of participants in the study Figure : Consort diagram; the status of participants in the study Figure a. Time to first colorectal cancer in those randomized to aspirin compared with those randomized to aspirin placebo (AP). Kaplan-Meier

More information

Programme - Wednesday, 5 September

Programme - Wednesday, 5 September Programme - Wednesday, 5 September 15th Meeting of the EAU Robotic Urology Section Room: Auditorium Actual programme might be subject to change due to live surgery Live broadcasts from Institut Paoli-Calmettes

More information

What do blood cancer patients want? (And what do we need and expect too?)

What do blood cancer patients want? (And what do we need and expect too?) What do blood cancer patients want? (And what do we need and expect too?) John Reeve, Consumer Rep Haem. Onc. CSG Richard Stephens, Patient Member, NCIN Haematology SSCRG Delivering clinical research to

More information

Trends and disparities in cancer in Aotearoa/ NZ

Trends and disparities in cancer in Aotearoa/ NZ Trends and disparities in cancer in Aotearoa/ NZ Professor Diana Sarfati #cancercrossroads @DiSarfati Why cancer? Estimated number of incident cases from 2018 to 2040 in New Zealand, all cancers, both

More information